Toinv

Your Ramblings may be just that - but you can be sure that Hepa has a long term strategy and it may be close to fulfillment. The white knight may eventually control the empire. Hepa originally came in at 2.67 per share to save the day and fund the betonmace trial and followed that up with the LOC payoff. We now wait for the sample size evaluation. If Resverlogix needs to pump more cash into a larger trial who they gonna call? 

One comment that DM made has always bothered me - the flippant remark that a Nasdaq listing was too costly - he subsequently went to the Hepa well below the initial 2.67 Hepa buy in and they seized on the opportunity placing them at 43% with a RofFF on the US market.  And now the coffers are nearly deplete again. What happens this time? 

Chicagoest